Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03484299 · ClinicalTrials.gov registry record · Phase 1
Chemotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma
A Phase 1 study of Pancreas Cancer, sponsored by University of Louisville.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT03484299: Recruiting Phase 1 study of Pancreas Cancer, sponsored by University of Louisville.
NCT03484299 is a Phase 1 study of Pancreas Cancer that is actively recruiting participants, run by University of Louisville. The registered enrollment target is 20 participants, below the 907-participant average among 54 other Pancreas Cancer trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03484299, a Phase 1 study of Pancreas Cancer, is actively recruiting participants, sponsored by University of Louisville.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
Compare the efficacy and tolerability of IRE in combination with either FOLFIRINOX or gemcitabine in patients with locally advanced pancreatic cancer.
Primary Outcome
Adverse and Serious Adverse events will be collected and analyzed
Conditions Studied
Interventions
- DRUG Gemcitabine
- DRUG FOLFIRINOX
- PROCEDURE Irreversible Electroporation (IRE)
Study Locations (1)
Kentucky
- University of Louisville - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2018-05-30 |
| Est. Completion | 2027-07-31 |
| Phase | Phase 1 |
What NCT03484299 shows while recruiting
NCT03484299 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 907-participant average among 54 other Pancreas Cancer trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Pancreas Cancer appearing as the primary indexed condition, and to 3 interventions - of which Gemcitabine is the first listed.
NCT03484299 reports a single indexed study location in Kentucky.
Frequently Asked Questions
What is clinical trial NCT03484299 about?
NCT03484299 is a clinical study titled "Chemotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma". Compare the efficacy and tolerability of IRE in combination with either FOLFIRINOX or gemcitabine in patients with locally advanced pancreatic cancer.
What is the current status of trial NCT03484299?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2018-05-30. Estimated completion is 2027-07-31.
What conditions does trial NCT03484299 study?
This clinical trial studies the following conditions: Pancreas Cancer.
What interventions are being tested in trial NCT03484299?
The interventions under investigation include: Gemcitabine (DRUG), FOLFIRINOX (DRUG), Irreversible Electroporation (IRE) (PROCEDURE).
Who is sponsoring clinical trial NCT03484299?
This trial is sponsored by University of Louisville, which has 217 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03484299 being conducted?
This trial has 1 study location across Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreas Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03484299's enrollment target sits among peer trials
20 51st of 54 higher than 4 of 54 other Pancreas Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pancreas Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
RECRUITING · Phase 1
-
Nab-Paclitaxel + Cisplatin + Gemcitabine + TTF in pt. w/ Metastatic PAC
RECRUITING · Phase 1
-
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
RECRUITING · Phase 1
-
Study of EGFRBi Armed Fresh PBMC in Metastatic or Unresectable Pancreatic Cancer
RECRUITING · Phase 1
-
Autologous CAR-T Cells Targeting B7-H3 in PDAC
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI